Amicus Therapeutics, Inc. (FOLD)

11.17 -0.62 (-5.26%) At close: 4:00PM EST

Amicus Therapeutics, Inc.

3675 Market Street
Philadelphia, PA 19104
United States
215-921-7600
http://www.amicusrx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 584

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. John F. Crowley	Chairman & CEO	1.96M	2.15M	1967
Mr. Bradley L. Campbell M.B.A.	Pres, COO & Director	899.2k	52.17k	1976
Ms. Daphne E. Quimi	Chief Financial Officer	630.45k	N/A	1966
Dr. Hung Viet Do	Chief Scientific Officer	637.43k	319.26k	1968
Ms. Ellen S. Rosenberg	Chief Legal Officer & Corp. Sec.	686.59k	N/A	1963
Ms. Samantha Prout	VP of Fin., Global Controller & Principal Accounting Officer	N/A	N/A	1978
Dr. Enrique Diloné	Sr. VP of Technical Operations	N/A	N/A	1967
Andrew Faughnan	Director of Investor Relations	N/A	N/A	N/A
Mr. Patrik S. Florencio	Sr. VP, Global Chief Compliance & Risk Officer	N/A	N/A	N/A
Ms. Diana Moore	Head of Global Corp. Communications	N/A	N/A	N/A

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Philadelphia, Pennsylvania.

Corporate Governance

Amicus Therapeutics, Inc.’s ISS Governance QualityScore as of December 3, 2020 is 4. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.